Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, With Executive Guides and Customization" has been added to ResearchAndMarkets.com's offering.
Advanced diagnostic technologies are emerging as a critical component of global efforts to reduce the growing threat of antimicrobial resistance. By enabling faster and more accurate pathogen identification, these technologies can support informed treatment decisions, strengthen antimicrobial stewardship and reduce unnecessary exposure to antibiotics. As healthcare systems seek practical solutions while new antibiotics remain in development, demand for innovative infectious disease diagnostics is expected to create significant opportunities for technology providers, laboratories and healthcare organizations.
The report examines the evolving technology landscape for diagnosing pathogens and infections, with coverage extending beyond gene sequencing. It assesses emerging diagnostic approaches designed to improve the speed, precision and clinical value of infectious disease testing. The analysis also considers how innovation may influence patient management, laboratory workflows and the broader response to drug-resistant infections.
Antimicrobial resistance continues to place pressure on healthcare systems, clinicians and public health authorities. Diagnostic technologies can help address this challenge by providing actionable information that may guide the selection of appropriate therapies. Their role is becoming increasingly important as healthcare providers balance the need for timely treatment with the responsible use of existing antimicrobial medicines.
In addition to reviewing the technology environment, the report identifies the 6 Key Large Pathogen Opportunities shaping the market. These opportunities offer insight into areas where diagnostic demand, clinical need and commercial potential may converge. Market forecasts are included to help readers evaluate prospective growth and understand how different pathogen segments could contribute to the development of the infectious disease diagnostics market.
The report also profiles more than 30 companies operating across this competitive landscape. Coverage includes both large and small organizations developing technologies for pathogen detection and infection diagnosis. These profiles provide a structured view of market participation, innovation activity and the range of businesses seeking to address unmet diagnostic needs. The company analysis can assist readers in monitoring established participants, emerging developers and potential areas of strategic interest.
As the market expands, diagnostic developers will need to demonstrate that their technologies can deliver reliable results while fitting effectively within clinical and laboratory settings. Adoption may depend on multiple factors, including performance, testing speed, workflow compatibility, accessibility and the ability to generate information that supports treatment decisions. Market participants must also navigate changing healthcare priorities and the increasing emphasis on antimicrobial stewardship.
The report provides market intelligence for organizations evaluating opportunities in antimicrobial resistance diagnostics, pathogen detection and infectious disease testing. Its combination of technology analysis, pathogen-focused market forecasts and company profiles supports strategic planning across the sector. The findings may be relevant to diagnostic companies, healthcare suppliers, investors, research organizations, laboratories and other stakeholders seeking a clearer perspective on the direction of this developing market.
Although diagnostics alone cannot eliminate antimicrobial resistance, their contribution to improved infection management is becoming more prominent. Continued advances beyond gene sequencing could broaden testing capabilities and help healthcare professionals make faster, evidence-based decisions. With commercial activity increasing and more than 30 companies represented in the analysis, the report highlights a dynamic market positioned to play an important role in the global response to antimicrobial resistance.
Key Topics Covered:
1 Market Guides
1.1 Antimicrobial Resistance - Strategic Situation Analysis
1.2 Guide for Executives and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 The Threat and Opportunity of Antimicrobial Resistance
2.2 Defining the Opportunity
2.2.1 Revenue Market Size
2.3 Methods and Sources
2.3.1 Methodology
2.3.2 Sources
2.3.3 Authors
2.4 Perspective: Healthcare and the IVD Industry
2.4.1 Global Healthcare Spending
2.5 Spending on Diagnostics
2.5.1 Important Role of Insurance for Diagnostics
3 Overview of a Dynamic Market
3.1 Players in a Dynamic Market
3.1.1 Diagnostic Test Developer
3.1.2 Instrumentation Supplier
3.1.3 Chemical/Reagent Supplier
3.1.4 Pathology Supplier
3.1.5 Independent Clinical Laboratory
3.1.6 Public National/regional Laboratory
3.1.7 Hospital Laboratory
3.1.8 Physicians Office Lab (POLS)
3.1.9 Audit Body
3.1.10 Certification Body
3.2 Understanding Antimicrobial Resistance
3.2.1 What is Antimicrobial Resistance (AMR)
3.2.2 Bacteria and Other Microbes
3.2.3 The History of Antibiotics
3.2.4 The Role of Animal Husbandry
3.2.5 The Implications of Horizontal Transfer
3.2.6 The Threat of AMR
3.3 The Changing Road to New Antibiotics & Technologies
3.4 The Key Role of Diagnostics in AMR
4 The Market Opportunity of AMR
4.1 The Key Large Market Opportunities in AMR
4.1.1 Streptococcus Pneumoniae (DRSP)
4.1.2 Campylobacter (DRC)
4.1.3 Clostridium Difficile (CD)
4.1.4 Staphylococcus aureus (MRSA)
4.1.5 Neisseria gonorrhoeae (DRNG)
4.1.6 Salmonella (DRNTS)
4.2 Diagnostic Technology Development Opportunities
4.2.1 What's Wrong with Microbiology
4.2.2 The Features Battleground of Infectious Disease Diagnostics
4.2.3 Multiplex vs. POC/Rapid
4.2.4 The Miracle of Genetics
4.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation
4.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.
4.2.7 Markers of Resistance.
4.2.8 What Happens to the Microbiology Lab?
5 Antibiotic Resistance Diagnostics Recent Developments
5.1 Antibiotic Resistance Recent Developments
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 FDA Clears New bioMerieux Diagnostic System and Panel
5.3 Selux Diagnostics Phenotyping System Gets FDA Approval
5.4 New diagnostics to tackle drug resistant infections
5.5 Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels
5.6 Three companies join forces to tackle antimicrobial resistance (AMR)
5.7 T2 Biosystems Exercises BARDA Option
5.8 OpGen to Ramp up Use of Acuitas AMR Gene Panel
5.9 BD Partners With Pfizer, Wellcome to Study AMR Dx
5.10 Sepsis Test Developers Accelerate Plans
5.11 OpGen Receives FDA Clearance for AMR Panel
5.12 Visby Medical - Rapid Uptake of Handheld PCR Test for STIs
5.13 MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
5.14 BioMerieux Receives CE Mark for Vitek Clinical Microbiology System
5.15 Hologic to Acquire Mobidiag
5.16 Campylobacter strains exchange genes
5.17 Disinfection spreads antimicrobial resistance
5.18 Molzym, Fraunhofer Developing Rapid Sepsis Dx
5.19 Illumina, IDbyDNA Build NGS-Based Respiratory Panel
5.20 Accelerate Diagnostics Expands AMR Testing
5.21 Rapid diagnostics linked to optimal antibiotics
5.22 Visby Medical Wins AMR Diagnostic Competition
5.23 DNAe Technology SARS-CoV-2 Sequences
5.24 Infections with foodborne bacteria becoming harder to treat
5.25 Dust is sharing antibiotic resistance genes
6 Key AMR Diagnostics Companies
6.1 1928 Diagnostics
6.2 Abacus Diagnostica
6.3 Abbott Laboratories
6.4 Accelerate Diagnostics
6.5 ADT Biotech
6.6 Beckman Coulter Diagnostics
6.7 Becton, Dickinson and Company
6.8 Binx Health
6.9 bioMerieux Diagnostics
6.10 Bio-Rad Laboratories, Inc.
6.11 Cepheid (Danaher)
6.12 Curetis N.V. / Curetis GmbH
6.13 Day Zero Diagnostics.
6.14 Enzo Biochem
6.15 Eurofins Scientific
6.16 Fusion Genomics.
6.17 GeneFluidics
6.18 Genetic Signatures
6.19 Great Basin Corporation
6.20 Hologic
6.21 Hutman Diagnostics
6.22 Inflammatix
6.23 Linear Diagnostics.
6.24 Lumos Diagnostics
6.25 Millipore Sigma
6.26 OpGen
6.27 Ortho Clinical Diagnostics
6.28 Perkin Elmer
6.29 Qiagen
6.30 Roche Molecular Diagnostics
6.31 SeLux Diagnostics
6.32 Sense Biodetection
6.33 Siemens Healthineers
6.34 Sysmex
6.35 Thermo Fisher Scientific Inc.
6.36 Visby Medical
7 The Global Market for Antimicrobial Resistance Diagnostics
7.1 Global Market Overview by Country.
7.1.1 Table - Global Market by Country
7.1.2 Chart - Global Market by Country
7.2 Global Market by Pathogen - Overview
7.2.1 Table - Global Market by Pathogen
7.2.2 Chart - Global Market by Pathogen - Base/End Year Comparison
7.2.3 Chart - Global Market by Pathogen - Base Year
7.2.4 Chart - Global Market by Pathogen - End Year
7.2.5 Chart - Global Market by Pathogen - Share by Year
7.2.6 Chart - Global Market by Pathogen - Segment Growth
7.3 Global Market by Technology - Overview
7.3.1 Table - Global Market by Technology
7.3.2 Chart - Global Market by Technology - Base/End Year Comparison
7.3.3 Chart - Global Market by Technology - Base Year
7.3.4 Chart - Global Market by Technology - End Year
7.3.5 Chart - Global Market by Technology - Share by Year
7.3.6 Chart - Global Market by Technology - Segment Growth
8 Global Antibiotic Resistance Diagnostic Markets - By Pathogen
8.1 Drug Resistant Streptococcus Pneumoniae - DRSP
8.1.1 Table DRSP - by Country
8.1.2 Chart - DRSP Growth
8.2 Drug Resistant Campylobacter - DRC
8.2.1 Table DRC - by Country
8.2.2 Chart - DRC Growth
8.3 Clostridium Difficile - CD
8.3.1 Table CD - by Country
8.3.2 Chart - CD Growth
8.4 Methicillin Resistant Staphylococcus Aureus - MRSA
8.4.1 Table MRSA - by Country
8.4.2 Chart - MRSA Growth
8.5 Drug Resistant Neisseria Gonorrhoeae - DRNG
8.5.1 Table DRNG - by Country
8.5.2 Chart - DRNG Growth
8.6 Drug Resistant Salmonella - DRNTS
8.6.1 Table DRNTS - by Country
8.6.2 Chart - DRNTS Growth
9 Global Antibiotic Resistance Diagnostic Markets - by Technology
9.1 Microbiology Culture
9.1.1 Table Culture - by Country
9.1.2 Chart - Culture Growth
9.2 Immunoassay
9.2.1 Table Immunoassay - by Country
9.2.2 Chart - Immunoassay Growth
9.3 PCR
9.3.1 Table PCR - by Country
9.3.2 Chart - PCR Growth
9.4 NGS
9.4.1 Table NGS - by Country
9.4.2 Chart - NGS Growth
9.5 Mass Spectrometry - MS
9.5.1 Table MS - by Country
9.5.2 Chart - MS Growth
9.6 Rapid and Point of Care - Rapid/POC
9.6.1 Table Rapid/POC - by Country
9.6.2 Chart - Rapid/POC Growth
10 Vision of the Future of AMR Diagnostics
11 Appendices
11.1 United States Medicare System: Clinical Laboratory Fees Schedule
List of Tables [26]
List of Figures [28]
Companies Featured
- 1928 Diagnostics
- Abacus Diagnostica
- Abbott Laboratories
- Accelerate Diagnostics
- ADT Biotech
- Beckman Coulter Diagnostics
- Becton, Dickinson and Company
- Binx Health
- bioMerieux Diagnostics
- Bio-Rad Laboratories, Inc.
- Cepheid (Danaher)
- Curetis N.V. / Curetis GmbH
- Day Zero Diagnostics.
- Enzo Biochem
- Eurofins Scientific
- Fusion Genomics.
- GeneFluidics
- Genetic Signatures
- Great Basin Corporation
- Hologic
- Hutman Diagnostics
- Inflammatix
- Linear Diagnostics.
- Lumos Diagnostics
- Millipore Sigma
- OpGen
- Ortho Clinical Diagnostics
- Perkin Elmer
- Qiagen
- Roche Molecular Diagnostics
- SeLux Diagnostics
- Sense Biodetection
- Siemens Healthineers
- Sysmex
- Thermo Fisher Scientific Inc.
- Visby Medical
For more information about this report visit https://www.researchandmarkets.com/r/ydtmvz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
